Abionyx Pharma SA (ABNX) - Total Liabilities

Latest as of June 2025: €7.56 Million EUR ≈ $8.84 Million USD

Based on the latest financial reports, Abionyx Pharma SA (ABNX) has total liabilities worth €7.56 Million EUR (≈ $8.84 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Abionyx Pharma SA - Total Liabilities Trend (2013–2024)

This chart illustrates how Abionyx Pharma SA's total liabilities have evolved over time, based on quarterly financial data. See Abionyx Pharma SA (ABNX) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Abionyx Pharma SA Competitors by Total Liabilities

The table below lists competitors of Abionyx Pharma SA ranked by their total liabilities.

Company	Country	Total Liabilities
United Bancorp Inc NASDAQ:UBCP	USA	$791.00 Million
Vascon Engineers Limited NSE:VASCONEQ	India	Rs12.12 Billion
Zhulian Corporation Bhd KLSE:5131	Malaysia	RM32.93 Million
LI Ming Development Construction Co Ltd TWO:6212	Taiwan	NT$7.36 Billion
Negri Sembilan Oil Palms Bhd KLSE:2038	Malaysia	RM223.87 Million
Vittia Fertilizantes SA:VITT3	Brazil	R$312.37 Million
Quantum Graphite Ltd AU:QGL	Australia	AU$10.23 Million
Charlton Aria Acquisition Corporation Class A Ordinary Shares NASDAQ:CHAR	USA	$1.90 Million

Liability Composition Analysis (2013–2024)

This chart breaks down Abionyx Pharma SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ABNX company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.40	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.40	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.58	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Abionyx Pharma SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Abionyx Pharma SA (2013–2024)

The table below shows the annual total liabilities of Abionyx Pharma SA from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	€6.03 Million ≈ $7.05 Million	-12.82%
2023-12-31	€6.91 Million ≈ $8.08 Million	-20.13%
2022-12-31	€8.65 Million ≈ $10.12 Million	-22.42%
2021-12-31	€11.15 Million ≈ $13.04 Million	+204.86%
2020-12-31	€3.66 Million ≈ $4.28 Million	+2.12%
2019-12-31	€3.58 Million ≈ $4.19 Million	-61.46%
2018-12-31	€9.30 Million ≈ $10.87 Million	-1.18%
2017-12-31	€9.41 Million ≈ $11.00 Million	-34.91%
2016-12-31	€14.46 Million ≈ $16.90 Million	+11.98%
2015-12-31	€12.91 Million ≈ $15.09 Million	+19.24%
2014-12-31	€10.82 Million ≈ $12.66 Million	+39.44%
2013-12-31	€7.76 Million ≈ $9.08 Million	--

About Abionyx Pharma SA

PA:ABNX France Biotechnology

Market Cap

$92.39 Million

€79.03 Million EUR

Market Cap Rank

#19581 Global

#297 in France

Share Price

€2.24

Change (1 day)

-12.84%

52-Week Range

€1.20 - €5.00

All Time High

€12.79